The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors
Open accessAbstract
Invasion and metastasis increase after the inhibition of VEGF signaling in some preclinical tumor models. In the present study we asked whether selective VEGF inhibition is sufficient to increase invasion and metastasis and whether selective c-Met inhibition is sufficient to block this effect. Treatment of pancreatic neuroendocrine tumors in RIP-Tag2 mice with a neutralizing anti-VEGF antibody reduced tumor burden but increased tumor hypoxia, hypoxia-inducible factor-1α, and c-Met activation and also increased invasion and metastasis. However, invasion and metastasis were reduced by concurrent inhibition of c-Met by PF-04217903 or PF-02341066 (crizotinib). A similar benefit was found in orthotopic Panc-1 pancreatic carcinomas treated with sunitinib plus PF-04217903 and in RIP-Tag2 tumors treated with XL184 (cabozantinib), which simultaneously blocks VEGF and c-Met signaling. These findings document that invasion and metastasis are promoted by selective inhibition of VEGF signaling and can be reduced by the concurrent inhibition of c-Met. Significance: This report examines the mechanism of increased tumor aggressiveness after anti-VEGF therapy and presents evidence for roles of vascular pruning, hypoxia, and c-Met activation. The results show that simultaneous inhibition of c-Met and VEGF signaling not only slows tumor growth but also reduces invasion and metastasis. Cancer Discovery; 2(3); 270–87. ©2012 AACR. Read the Commentary on this article by Lynn and Brekken, p. 211 This article is highlighted in the In This Issue feature, p. 193
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature Reviews Cancer · doi:10.1038/nrc822 · Cited by 6,628
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
EMT, the cytoskeleton, and cancer cell invasion
Yilmaz, M., & Christofori, G. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9169-0 · Cited by 1,788
The snail superfamily of zinc-finger transcription factors
Nieto, M. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm757 · Cited by 1,719
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
Ebos, J. M. L., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.021 · Cited by 1,709
Self-citationHypoxia signalling in cancer and approaches to enforce tumour regression
Pouysségur, J., Dayan, F., & Mazure, N. M. (2006) · Nature · doi:10.1038/nature04871 · Cited by 1,676
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
A causal role for E-cadherin in the transition from adenoma to carcinoma
Perl, A.-K., Wilgenbus, P., Dahl, U., Semb, H., & Christofori, G. (1998) · Nature · doi:10.1038/32433 · Cited by 1,424
Yakes, F. M., Chen, J., Tan, J., Yamaguchi, K., Shi, Y., Yu, P., Qian, F., Chu, F., Bentzien, F., Cancilla, B., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0264 · Cited by 1,336
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00085-0 · Cited by 1,311
Hanahan, D. (1985) · Nature · doi:10.1038/315115a0 · Cited by 1,281
MET signalling: principles and functions in development, organ regeneration and cancer
Trusolino, L., Bertotti, A., & Comoglio, P. M. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3012 · Cited by 1,240
Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice
Bergers, G., Javaherian, K., Lo, K.-M., Folkman, J., & Hanahan, D. (1999) · Science · doi:10.1126/science.284.5415.808 · Cited by 988 · cited 1×
“(1) RGB images were converted to 8-bit gray scale; (2) the tumor border was outlined by the freehand tool; (3) the region outside the tumor was filled black; (4) a threshold of approximately 30 in the range of 0 to 255 was applied to include all tumor cells; (5) the image was converted to binary (black and white) base…”
MethodInai, T., Mancuso, M., Hashizume, H., Baffert, F., Haskell, A., Baluk, P., Hu-Lowe, D. D., Shalinsky, D. R., Thurston, G., Yancopoulos, G. D., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63273-7 · Cited by 757
Self-citationChristensen, J. G., Zou, H. Y., Arango, M. E., Li, Q., Lee, J. H., McDonnell, S. R., Yamazaki, S., Alton, G. R., Mroczkowski, B., & Los, G. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0365 · Cited by 649
Self-citationGjerdrum, C., Tiron, C., Høiby, T., Stefansson, I., Haugen, H., Sandal, T., Collett, K., Li, S., McCormack, E., Gjertsen, B. T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909333107 · Cited by 594
Kurzrock, R., Sherman, S. I., Ball, D. W., Forastiere, A. A., Cohen, R. B., Mehra, R., Pfister, D. G., Cohen, E. E. W., Janisch, L., Nauling, F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.4145 · Cited by 550
Rubenstein, J. L., Kim, J., Ozawa, T., Zhang, M., Westphal, M., Deen, D. F., & Shuman, M. A. (2000) · Neoplasia · doi:10.1038/sj.neo.7900102 · Cited by 509
Targeting the c-Met Signaling Pathway in Cancer
Peruzzi, B., & Bottaro, D. P. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0818 · Cited by 448
TGF-β/TGF-β receptor system and its role in physiological and pathological conditions
Santibañez, J. F., Quintanilla, M., & Bernabeu, C. (2011) · Clinical Science · doi:10.1042/cs20110086 · Cited by 397
c-Met Is a Marker of Pancreatic Cancer Stem Cells and Therapeutic Target
Li, C., Wu, J., Hynes, M., Dosch, J., Sarkar, B., Welling, T. H., Pasca di Magliano, M., & Simeone, D. M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.08.009 · Cited by 386
Qian, F., Engst, S., Yamaguchi, K., Yu, P., Won, K.-A., Mock, L., Lou, T., Tan, J., Li, C., Tam, D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4889 · Cited by 350
Cross-talk between Epidermal Growth Factor Receptor and c-Met Signal Pathways in Transformed Cells*
Jo, M., Stolz, D. B., Esplen, J. E., Dorko, K., Michalopoulos, G. K., & Strom, S. C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.8806 · Cited by 347
Targeting the tumor and its microenvironment by a dual-function decoy Met receptor
Michieli, P., Mazzone, M., Basilico, C., Cavassa, S., Sottile, A., Naldini, L., & Comoglio, P. M. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.05.032 · Cited by 299
Wang, R., Ferrell, L. D., Faouzi, S., Maher, J. J., & Bishop, J. M. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.153.5.1023 · Cited by 281
Lengyel, E., Prechtel, D., Resau, J. H., Gauger, K., Welk, A., Lindemann, K., Salanti, G., Richter, T., Knudsen, B., Vande Woude, G. F., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.20598 · Cited by 273
Lopez, T., & Hanahan, D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00055-7 · Cited by 268
VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
You, W.-K., Sennino, B., Williamson, C. W., Falcón, B., Hashizume, H., Yao, L.-C., Aftab, D. T., & McDonald, D. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2527 · Cited by 259
Self-citationSawada, K., Radjabi, A. R., Shinomiya, N., Kistner, E., Kenny, H., Becker, A. R., Turkyilmaz, M. A., Salgia, R., Yamada, S. D., Vande Woude, G. F., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1147 · Cited by 258
The MET receptor tyrosine kinase in invasion and metastasis
Benvenuti, S., & Comoglio, P. M. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21183 · Cited by 253
Narayana, A., Kelly, P., Golfinos, J., Parker, E., Johnson, G., Knopp, E., Zagzag, D., Fischer, I., Raza, S., Medabalmi, P., et al. (2009) · Journal of Neurosurgery · doi:10.3171/2008.4.17492 · Cited by 243
Jin, H., Yang, R., Zheng, Z., Romero, M., Ross, J., Bou-Reslan, H., Carano, R. A. D., Kasman, I., Mai, E., Young, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5960 · Cited by 220
Maione, F., Molla, F., Meda, C., Latini, R., Zentilin, L., Giacca, M., Seano, G., Serini, G., Bussolino, F., & Giraudo, E. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36308 · Cited by 219
Expression of c-met is a strong independent prognostic factor in breast carcinoma
Ghoussoub, R. A. D., Dillon, D. A., D'Aquila, T., Rimm, E. B., Fearon, E. R., & Rimm, D. L. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980415)82:8<1513::aid-cncr13>3.0.co;2-7 · Cited by 217
Qi, J., McTigue, M. A., Rogers, A., Lifshits, E., Christensen, J. G., Jänne, P. A., & Engelman, J. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1623 · Cited by 216
Self-citationCrosstalk in Met receptor oncogenesis
Lai, A. Z., Abella, J. V., & Park, M. (2009) · Trends in Cell Biology · doi:10.1016/j.tcb.2009.07.002 · Cited by 213
Cullen, M., Elzarrad, M. K., Seaman, S., Zudaire, E., Stevens, J., Yang, M. Y., Li, X., Chaudhary, A., Xu, L., Hilton, M. B., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017192108 · Cited by 207
Ponzo, M. G., Lesurf, R., Petkiewicz, S., O'Malley, F. P., Pinnaduwage, D., Andrulis, I. L., Bull, S. B., Chughtai, N., Zuo, D., Souleimanova, M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810402106 · Cited by 203
Bruns, C. J., Liu, W., Davis, D. W., Shaheen, R. M., McConkey, D. J., Wilson, M. R., Bucana, C. D., Hicklin, D. J., & Ellis, L. M. (2000) · Cancer · doi:10.1002/1097-0142(20000801)89:3<488::aid-cncr3>3.0.co;2-x · Cited by 189
Prognostic significance of c‐Met expression in glioblastomas
Kong, D., Song, S., Kim, D., Joo, K. M., Yoo, J., Koh, J. S., Dong, S. M., Suh, Y., Lee, J., Park, K., et al. (2009) · Cancer · doi:10.1002/cncr.23972 · Cited by 187
Cross‐talk between the VEGF‐A and HGF signalling pathways in endothelial cells
Sulpice, E., Ding, S., Muscatelli‐Groux, B., Bergé, M., Han, Z. C., Plouet, J., Tobelem, G., & Merkulova‐Rainon, T. (2009) · Biology of the Cell · doi:10.1042/bc20080221 · Cited by 178
Cheng, N., Chytil, A., Shyr, Y., Joly, A., & Moses, H. L. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2203 · Cited by 178
Fleming, J. B., Shen, G.-L., Holloway, S. E., Davis, M., & Brekken, R. A. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-04-0206 · Cited by 176
Out of air is not out of action
Bottaro, D. P., & Liotta, L. A. (2003) · Nature · doi:10.1038/423593a · Cited by 168
McDermott, U., Pusapati, R. V., Christensen, J. G., Gray, N. S., & Settleman, J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3620 · Cited by 161
Self-citationSennino, B., Falcón, B. L., McCauley, D., Le, T., McCauley, T. G., Kurz, J. C., Haskell, A., Epstein, D. M., & McDonald, D. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0293 · Cited by 159
Self-citationChristensen, J. G. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm408 · Cited by 155
Self-citationGaspar, N. J., Li, L., Kapoun, A. M., Medicherla, S., Reddy, M., Li, G., O’Young, G., Quon, D. H., Henson, M., Damm, D. L., et al. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.029025 · Cited by 133
Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer
Graveel, C. R., DeGroot, J. D., Su, Y., Koeman, J. M., Dykema, K. J., Leung, S. C. Y., Snider, J., Davies, S. R., Swiatek, P. J., Cottingham, S. L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810403106 · Cited by 116
HGF-independent potentiation of EGFR action by c-Met
Dulak, A. M., Gubish, C. T., Stabile, L. P., Henry, C., & Siegfried, J. M. (2011) · Oncogene · doi:10.1038/onc.2011.84 · Cited by 115
Distinct ligand binding sites in integrin α3β1 regulate matrix adhesion and cell–cell contact
Zhang, F., Tom, C. C., Kugler, M. C., Ching, T., Kreidberg, J. A., Wei, Y., & Chapman, H. A. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200304065 · Cited by 112
Self-citationHussain, M., Smith, M. R., Sweeney, C. J., Corn, P. G., Elfiky, A. A., Gordon, M. S., Haas, N. B., Harzstark, A. L., Kurzrock, R., Lara, P. N., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.4516 · Cited by 111
Nakagawa, T., Tohyama, O., Yamaguchi, A., Matsushima, T., Takahashi, K., Funasaka, S., Shirotori, S., Asada, M., & Obaishi, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01343.x · Cited by 106
Timofeevski, S. L., McTigue, M. A., Ryan, K., Cui, J., Zou, H. Y., Zhu, J. X., Chau, F., Alton, G., Karlicek, S., Christensen, J. G., et al. (2009) · Biochemistry · doi:10.1021/bi900438w · Cited by 100
Self-citationXu, L., Nilsson, M. B., Saintigny, P., Cascone, T., Herynk, M. H., Du, Z., Nikolinakos, P. G., Yang, Y., Prudkin, L., Liu, D., et al. (2010) · Oncogene · doi:10.1038/onc.2010.16 · Cited by 98
Bloomston, M., Shafii, A. E., Zervos, E. E., & Rosemurgy, A. S. (2002) · Journal of Surgical Research · doi:10.1006/jsre.2001.6318 · Cited by 96
Dai, C., Huh, C.-G., Thorgeirsson, S. S., & Liu, Y. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62987-2 · Cited by 81
Beck, A. W., Luster, T. A., Miller, A. F., Holloway, S. E., Conner, C. R., Barnett, C. C., Thorpe, P. E., Fleming, J. B., & Brekken, R. A. (2005) · International Journal of Cancer · doi:10.1002/ijc.21684 · Cited by 74
Yu, Y., & Merlino, G. T. (2002) · PubMed · Cited by 64
Sampson, E. R., Martin, B., Morris, A. E., Xie, C. L., Schwarz, E. M., O’Keefe, R. J., & Rosier, R. N. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.336 · Cited by 51
Chun, M. G. H., Mao, J., Chiu, C. W., Balmain, A., & Hanahan, D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012705107 · Cited by 22
Cited by
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Abou-Alfa, G. K., Meyer, T., Cheng, A.-L., El-Khoueiry, A. B., Rimassa, L., Ryoo, B.-Y., Cicin, I., Merle, P., Chen, Y., Park, J.-W., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1717002 · Cited by 2,344
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
Choueiri, T. K., Escudier, B., Powles, T., Mainwaring, P. N., Rini, B. I., Donskov, F., Hammers, H., Hutson, T. E., Lee, J.-L., Peltola, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510016 · Cited by 1,239
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Vasudev, N. S., & Reynolds, A. R. (2014) · Angiogenesis · doi:10.1007/s10456-014-9420-y · Cited by 738
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer
Welti, J., Loges, S., Dimmeler, S., & Carmeliet, P. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70212 · Cited by 591
Metadata
- Authors
- Sennino, B., Ishiguro-Oonuma, T., Wei, Y., Naylor, R. M., Williamson, C. W., Bhagwandin, V., Tabruyn, S. P., You, W.-K., Chapman, H. A., Christensen, J. G., Aftab, D. T., & McDonald, D. M.
- Venue
- Cancer Discovery
- Published
- 2012-03-01
- Volume
- 2
- Issue
- 3
- Pages
- 270-287
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2039013742
- Cited by
- 408
- References
- 64
- FWCI
- 17.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.